• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
      • Kinases
      • Epigenetics
      • GPCR, NR, Ion-channel, Transporter
      • Ubiquitin & PROTAC
      • KRAS
      • COVID-19
      • Radiometric
      • Customized assay development
      • High throughput screening
      • MOA Study
    • Metabolic & Cardiovascular Diseases
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

Antibody-Drug Conjugation at ChemPartner

ChemPartner has a top-tier Antibody-Drug Conjugation (ADC) team spanning multiple areas, including antibody development, design and synthesis of linker and payload, conjugation chemistry, as well as ADC analytical, efficacy, toxicology, and DMPK studies. Using state-of-the-art technologies, our scientists have been helping numerous clients design novel ADCs and solve technical challenges in their ADC development processes. Please click on the following posters for more details.

An Anti-Her2 Antibody-Drug Conjugate XDCE-1 for Targeted Cancer Therapy

A series of novel Matansinol-derived toxins was designed, synthesized and assessed for their suitability in developing anti-Her2 antibody-drug conjugates. Among all ADCs tested, one demonstrated high potency, low hepatotoxicity and desired PK profile.

Synergistic Efficacy of an Anti-TPBG mAb-MMAE and an Anti-PD1 mAb

A humanized anti-TPBG mAb was developed and conjugated with MMAE. The resulting ADC was then studied by co-administration with an anti-PD1 mAB in a mouse model, where significant synergistic tumor growth inhibition and enhanced disease control were observed.

Antibody-Toxin Conjugate with a Novel Linker-payload

We have established a robust and efficient way to conjugate novel linker-payload compounds to antibodies using a semi-automatic system. This process is suitable for generating ADC products of consistent high quality, such as purify, DAR and bioactivities.